Targanta Study Shows Oritavancin Treatment Effective In A Mouse Model Of Anthrax / Medical News Today, 25 May 2007
http://www.medicalnewstoday.com/medicalnews.php?newsid=72072&nfid=nl
"Targanta Therapeutics Corporation announced today the results from a recent study demonstrating oritavancin as a potential therapy for treating exposure to Bacillus anthracis, the bacterium which causes anthrax, an acute infectious disease. Oritavancin, a novel semi- synthetic lipoglycopeptide antibiotic for the treatment of serious gram- positive infections, is Targanta's lead product currently in post-Phase 3 clinical development. This research was conducted and presented in partnership with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) at the American Society for Microbiology (ASM) 107th Annual General Meeting in Toronto, Ontario from May 21-25, 2007."